Identification of urine metabolites of TFAP, a cyclooxygenase-1 inhibitor

Abstract

Only a few COX-1-selective inhibitors are currently available, and the research on COX-1 selective inhibitors is not fully developed. The authors have produced several COX-1 selective inhibitors including N-(5-amino-2-pyridinyl)-4-trifluoromethylbenzamide: TFAP ( 3). Although 3 shows potent analgesic effect without gastric damage, the urine after administration of 3 becomes red–purple. Since the colored-urine should be avoided for clinical use, in this research we examined the cause of the colored-urine. UV–vis spectra and LC–MS/MS analyses of urine samples and metabolite candidates of 3 were performed to afford information that the main reason of the colored urine is a diaminopyridine ( 4), produced by metabolization of 3. This information is useful to design new COX-1 selective inhibitors without colored urine based on the chemical structure of 3.